14 results on '"Bonnie Harrington"'
Search Results
2. Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation
- Author
-
Shaneice Mitchell, Pu Zhang, Matthew Cannon, Larry Beaver, Amy Lehman, Bonnie Harrington, Deepa Sampath, John C. Byrd, and Rosa Lapalombella
- Subjects
NAMPT ,Leukemia ,Erythropoietin ,Niacin ,SOD ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract KPT-9274 is a phase 1 first-in-class dual PAK4/NAMPT inhibitor for solid tumor and non-Hodgkin’s lymphoma. It demonstrates pre-clinical efficacy toward a broad spectrum of acute myeloid leukemia (AML) subtypes by inhibiting NAMPT-dependent NAD+ production. NAMPT is the rate-limiting enzyme in the salvage metabolic pathway leading to NAD+ generation. Tumor cells which are deficient in de novo pathway enzyme NAPRT1 are addicted to NAMPT. In clinical trials, treatment with NAMPT inhibitors resulted in dose-limiting toxicities. In order to dissect the mechanism of toxicity, mice were treated with KPT-9274 and resulting toxicities were characterized histopathologically and biochemically. KPT-9274 treatment caused gender-dependent stomach and kidney injuries and anemia. Female mice treated with KPT-9274 had EPO deficiency and associated impaired erythropoiesis. KPT-9274 treatment suppressed SIRT3 expression and concomitantly upregulated acetyl-manganese superoxide dismutase (MnSOD) in IMCD3 cells, providing a mechanistic basis for observed kidney toxicity. Importantly, niacin supplementation mitigated KPT-9274-caused kidney injury and EPO deficiency without affecting its efficacy. Altogether, our study delineated the mechanism of KPT-9274-mediated toxicity and sheds light onto developing strategies to improve the tolerability of this important anti-AML inhibitor.
- Published
- 2021
- Full Text
- View/download PDF
3. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
- Author
-
Timothy L. Chen, Bonnie Harrington, Jean Truxall, Ronni Wasmuth, Alexander Prouty, Shelby Sloan, Amy M. Lehman, Deepa Sampath, Eric Orlemans, Robert A. Baiocchi, Lapo Alinari, John C. Byrd, Jennifer A. Woyach, and Erin Hertlein
- Subjects
Chronic lymphocytic leukemia ,Hsp90 ,BTK ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse on ibrutinib, and the progressive disease is often quite aggressive requiring immediate treatment. Several strategies are being pursued to treat patients who relapse on ibrutinib therapy. As the most common form of relapse is the development of a mutant form of BTK which limits ibrutinib binding, agents which lead to degradation of the BTK protein are a promising strategy. Our study explores the efficacy of the Hsp90 inhibitor, SNX-5422, in CLL. The SNX Hsp90 inhibitor was effective in primary CLL cells, as well as B-cell lines expressing either BTK wild type or C481 mutant BTK, which has been identified as the primary resistance mechanism to ibrutinib in CLL patients. Furthermore the combination of SNX-5422 and ibrutinib provided a remarkable in vivo survival benefit in the Eμ-TCL1 mouse model of CLL compared to the vehicle or single agent groups (51 day median survival in the vehicle and ibrutinib groups versus 100 day median survival in the combination). We report here preclinical data suggesting that the Hsp90 inhibitor SNX-5422, which has been pursued in clinical trials in both solid tumor and hematological malignancies, is a potential therapy for ibrutinib resistant CLL.
- Published
- 2021
- Full Text
- View/download PDF
4. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
- Author
-
Janek S. Walker, Zachary A. Hing, Bonnie Harrington, Jordan Baumhardt, Hatice Gulcin Ozer, Amy Lehman, Brian Giacopelli, Larry Beaver, Katie Williams, Jordan N. Skinner, Casey B. Cempre, Qingxiang Sun, Sharon Shacham, Benjamin R. Stromberg, Matthew K. Summers, Lynne V. Abruzzo, Laura Rassenti, Thomas J. Kipps, Sameer Parikh, Neil E. Kay, Kerry A. Rogers, Jennifer A. Woyach, Vincenzo Coppola, Yuh Min Chook, Christopher Oakes, John C. Byrd, and Rosa Lapalombella
- Subjects
XPO1 ,Chronic lymphocytic leukemia ,Mouse model ,Selinexor ,Sines ,Expression profiling ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Exportin 1 (XPO1/CRM1) is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia (CLL). Whole exome sequencing has identified hot-spot somatic XPO1 point mutations which we found to disrupt highly conserved biophysical interactions in the NES-binding groove, conferring novel cargo-binding abilities and forcing cellular mis-localization of critical regulators. However, the pathogenic role played by change-in-function XPO1 mutations in CLL is not fully understood. Methods We performed a large, multi-center retrospective analysis of CLL cases (N = 1286) to correlate nonsynonymous mutations in XPO1 (predominantly E571K or E571G; n = 72) with genetic and epigenetic features contributing to the overall outcomes in these patients. We then established a mouse model with over-expression of wildtype (wt) or mutant (E571K or E571G) XPO1 restricted to the B cell compartment (Eµ-XPO1). Eµ-XPO1 mice were then crossed with the Eµ-TCL1 CLL mouse model. Lastly, we determined crystal structures of XPO1 (wt or E571K) bound to several selective inhibitors of nuclear export (SINE) molecules (KPT-185, KPT-330/Selinexor, and KPT-8602/Eltanexor). Results We report that nonsynonymous mutations in XPO1 associate with high risk genetic and epigenetic features and accelerated CLL progression. Using the newly-generated Eµ-XPO1 mouse model, we found that constitutive B-cell over-expression of wt or mutant XPO1 could affect development of a CLL-like disease in aged mice. Furthermore, concurrent B-cell expression of XPO1 with E571K or E571G mutations and TCL1 accelerated the rate of leukemogenesis relative to that of Eµ-TCL1 mice. Lastly, crystal structures of E571 or E571K-XPO1 bound to SINEs, including Selinexor, are highly similar, suggesting that the activity of this class of compounds will not be affected by XPO1 mutations at E571 in patients with CLL. Conclusions These findings indicate that mutations in XPO1 at E571 can drive leukemogenesis by priming the pre-neoplastic lymphocytes for acquisition of additional genetic and epigenetic abnormalities that collectively result in neoplastic transformation.
- Published
- 2021
- Full Text
- View/download PDF
5. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
- Author
-
Lindsey T. Brinton, Pu Zhang, Katie Williams, Daniel Canfield, Shelley Orwick, Steven Sher, Ronni Wasmuth, Larry Beaver, Casey Cempre, Jordan Skinner, Matthew Cannon, Mukul Govande, Bonnie Harrington, Amy Lehman, John C. Byrd, Rosa Lapalombella, and James S. Blachly
- Subjects
Gilteritinib ,Midostaurin ,Synergy ,Combination therapy ,FLT3 ,BCL2 ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Acute myeloid leukemia (AML) is a heterogeneous and complex disease, and treatments for this disease have not been curative for the majority of patients. In younger patients, internal tandem duplication of FLT3 (FLT3-ITD) is a common mutation for which two inhibitors (midostaurin and gilteritinib) with varied potency and specificity for FLT3 are clinically approved. However, the high rate of relapse or failed initial response of AML patients suggests that the addition of a second targeted therapy may be necessary to improve efficacy. Using an unbiased large-scale CRISPR screen, we genetically identified BCL2 knockout as having synergistic effects with an approved FLT3 inhibitor. Here, we provide supportive studies that validate the therapeutic potential of the combination of FLT3 inhibitors with venetoclax in vitro and in vivo against multiple models of FLT3-ITD-driven AML. Our unbiased approach provides genetic validation for co-targeting FLT3 and BCL2 and repurposes CRISPR screening data, utilizing the genome-wide scope toward mechanistic understanding.
- Published
- 2020
- Full Text
- View/download PDF
6. Supplementary Figures & Tables from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
- Author
-
Rosa Lapalombella, John C. Byrd, Gideon Bollag, Ewy A. Mathé, Chao Zhang, Prabha Ibrahim, Gaston Habets, Bernice Matusow, Marika Nespi, Hamid Rezaei, Laura Sanftner, Jason Walters, Christina Tantoy, Adhirai Marimuthu, Todd Ewing, Ken Dong, Garson Tsang, Heidi Carias, Rafe Shellooe, Paul Severson, Songyuan Shi, Wayne Spevak, Ying Zhang, Yan Ma, Jiazhong Zhang, Lianbo Yu, Amy M. Lehman, Deepa Sampath, Jennifer A. Woyach, David M. Lucas, Virginia M. Goettl, Larry Beaver, Matthew Cannon, Elizabeth Baskin, Lindsey Brinton, Robert A. Baiocchi, Lapo Alinari, Tzung-Huei Lai, Katie Williams, Nicole R. Grieselhuber, Shaneice Mitchell, Bonnie Harrington, James S. Blachly, Zachary A. Hing, Ben Powell, Dalia El-Gamal, and Hatice Gulcin Ozer
- Abstract
Supplementary Figures S1-S7 with captions and Supplementary Tables
- Published
- 2023
- Full Text
- View/download PDF
7. Supplementary Methods from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
- Author
-
Rosa Lapalombella, John C. Byrd, Gideon Bollag, Ewy A. Mathé, Chao Zhang, Prabha Ibrahim, Gaston Habets, Bernice Matusow, Marika Nespi, Hamid Rezaei, Laura Sanftner, Jason Walters, Christina Tantoy, Adhirai Marimuthu, Todd Ewing, Ken Dong, Garson Tsang, Heidi Carias, Rafe Shellooe, Paul Severson, Songyuan Shi, Wayne Spevak, Ying Zhang, Yan Ma, Jiazhong Zhang, Lianbo Yu, Amy M. Lehman, Deepa Sampath, Jennifer A. Woyach, David M. Lucas, Virginia M. Goettl, Larry Beaver, Matthew Cannon, Elizabeth Baskin, Lindsey Brinton, Robert A. Baiocchi, Lapo Alinari, Tzung-Huei Lai, Katie Williams, Nicole R. Grieselhuber, Shaneice Mitchell, Bonnie Harrington, James S. Blachly, Zachary A. Hing, Ben Powell, Dalia El-Gamal, and Hatice Gulcin Ozer
- Abstract
Supplementary Methods
- Published
- 2023
- Full Text
- View/download PDF
8. LP-118, a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)
- Author
-
Kristin L Koenig, Colin Brame, Steven Sher, Larry Beaver, Casey B. Cempre, Katie Williams, Matthew Purcell, Bonnie Harrington, Yi Chen, Felai Tan, Stephen P. Anthony, Yu Chen, Yue Shen, John C. Byrd, and Rosa Lapalombella
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
- Full Text
- View/download PDF
9. Histiocytic Sarcoma and Bilateral Facial Vein Thrombosis in a Siberian Hamster (Phodopus sungorus)
- Author
-
Dondrae J, Coble, Margaret, Shoemaker, Bonnie, Harrington, Adrienne D, Dardenne, and Brad, Bolon
- Subjects
Male ,Venous Thrombosis ,Phodopus ,Hamster Model ,Cricetinae ,Face ,Animals ,Histiocytic Sarcoma - Abstract
A 21-mo-old, male Siberian hamster (Phodopus sungorus) presented with left-sided facial swelling, proptosis of the left eye, and blepharospasm of the right eye. The hamster had been used only for breeding. Because of the poor prognosis, the hamster was euthanized without additional diagnostic assays or treatments. Routine gross pathologic evaluation demonstrated exophthalmos and presumptive hyphema of the left eye, bilateral facial edema, freely movable nodules within the mesentery, white foci within the liver, and a large mass effacing the cranial pole of the right kidney. On histologic evaluation, the mesenteric nodules and liver foci expressed histiocytic marker CD163 and thus were diagnosed as sites of histiocytic sarcoma, whereas the kidney mass was a well-differentiated renal cell carcinoma. The facial swelling resulted from bilateral, chronic, severe, branching thrombi in many facial veins. Additional age-related histopathologic findings were observed in other organs, including diffuse glomerulopathy, nesidioblastosis (pancreatic islet neoformation), and multiple foci of severe cartilage degeneration in the axial skeleton. To our knowledge, this report provides the first description of histiocytic sarcoma in a Siberian hamster.
- Published
- 2015
10. The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing
- Author
-
Rogers, Kerry A., primary, El-Gamal, Dalia, additional, Bonnie, Harrington K., additional, Zachary, Hing A., additional, Virginia, Goettl M., additional, Rose, Mantel, additional, Smith, Lisa L., additional, Yu, Lianbo, additional, Johnson, Amy J., additional, Byrd, John C., additional, Lapalombella, Rosa, additional, and Woyach, Jennifer A., additional
- Published
- 2015
- Full Text
- View/download PDF
11. Adaptation of Cholinergic Enteric Neuromuscular Transmission in Diabetic Rat Small Intestine
- Author
-
Thomas V. Nowak, John H. Kalbfleisch, and Bonnie Harrington
- Subjects
Atropine ,Male ,medicine.medical_specialty ,Contraction (grammar) ,Physostigmine ,Endocrinology, Diabetes and Metabolism ,Neuromuscular Junction ,Neuromuscular transmission ,Tetrodotoxin ,Synaptic Transmission ,Streptozocin ,Diabetes Mellitus, Experimental ,Bethanechol Compounds ,Bethanechol Chloride ,Internal medicine ,Diabetes mellitus ,Intestine, Small ,Internal Medicine ,Animals ,Insulin ,Medicine ,Myenteric plexus ,Dose-Response Relationship, Drug ,business.industry ,Electric Conductivity ,Bethanechol ,medicine.disease ,Electric Stimulation ,Small intestine ,Rats ,Endocrinology ,medicine.anatomical_structure ,Cholinergic Fibers ,Cholinergic ,business ,medicine.drug - Abstract
Representative longitudinal muscle strips (6 × 10 mm) from distal small intestine were obtained from rats after 1, 2, and 3 mo of streptozocin-induced diabetes. The strips were stretched to their optimum lengths and subjected to electrical field stimulation (1-ms pulse duration, 30–270 mA, 10 Hz) in the presence of Krebs solution and Krebs solution plus 10−6 M atropine. Field stimulation produced atropine-sensitive and atropine-resistant contractions in all strips. After 1 mo, significant differences in the amplitudes of the atropine-sensitive contractions were found between the diabetic rats and nondiabetic controls. Insulintreated diabetic rats showed contraction responses that were intermediate in amplitude. After 2 mo, the difference between the control and diabetic groups was less evident but still significant. After 3 mo, the previously noted difference in the atropine-sensitive contractions between the diabetic and control groups had resolved. No significant differences among the three groups were noted in the amplitudes of the atropine-resistant contractions. Field stimulation delivered at pulse durations of 50 ms in the presence of neural blockade with tetrodotoxin (5 × 10−6 M) produced similar contraction amplitudes among the three groups at any respective time phase of the study. Dose-response studies of intestinal muscle after 3 mo of untreated diabetes showed normal tension development to both bethanechol chloride and physostigmine. These results indicate that streptozocin-induced diabetes is acutely associated with defective cholinergic neuromuscular transmission in the myenteric plexus of the distal small intestine The abnormality is less evident after 2 mo of untreated diabetes and resolves spontaneously after 3 mo. Insulin treatment appears to accelerate this resolution.
- Published
- 1990
- Full Text
- View/download PDF
12. Therapeutic treatment of multi-organ system, obstructive pulmonary and scleradermatous chronic graft-versus-host disease with the BTK and ITK inhibitor Ibrutinib (TRAN3P.873)
- Author
-
Ryan Flynn, Jason Dubovsky, Bonnie Harrington, Dawn Reichenbach, Zhong Yiming, Carrie Yang, Will Towns, Amy Lehman, Amy Johnson, Natarajan Muthusamy, Steven Devine, Samantha Jaglowski, Jonathan Serody, William Murphy, David Munn, Leo Luznik, Ivan Maillard, John Koreth, Corey Cutler, Robert Soiffer, Joseph Antin, Jerome Ritz, Angela Panoskaltsis-Mortari, John Byrd, and Bruce Blazar
- Subjects
Immunology ,Immunology and Allergy - Abstract
Chronic GVHD (cGVHD) is dependent on the ability of donor bone marrow (BM) B cells to produce pathogenic antibody (Ab) deposited in target organs, which is associated with increased germinal centers (GCs). BTK is necessary for B cells to enter GCs and ITK is necessary for T cell activation. We hypothesized that alloreactive GC B cells and T follicular helper cells require BTK or ITK and inhibition by ibrutinib (Ib) would prevent cGVHD. We evaluated the therapeutic effect of Ib in two models of cGVHD: a MHC-disparate (B6→B10.BR) multi-organ model complicated by bronchiolitis obliterans (BO) and a sclerodermatous (SCL) minor-mismatch (LP/J→B6) model. Mice treated with Ib had a decrease in pathogenic Ab, collagen deposition and GC B cells in target organs similar to healthy control mice. In contrast to cGVHD mice, pulmonary function in Ib treated mice was similar to control mice. To confirm that BTK and ITK are required for cGVHD we used donor mice with an ablation of BTK or ITK. Absence of BTK in B cells impeded GCs, Ab deposition and BO. Mice transplanted with T cells lacking ITK and WT BM did not develop BO. In the SCL model, mice treated with Ib did not develop clinical signs of cGVHD including less alopecia and SCL lesions. Furthermore, there was a decrease in lymphocyte infiltration surrounding the bronchioles and nephrons in treated mice. The inhibition of TEC-family kinases with Ib is a novel therapeutic for multi-organ system cGVHD with BO or SCL manifestations.
- Published
- 2014
- Full Text
- View/download PDF
13. Effect of Cholinergic Agonists on Muscle From Rodent Proximal and Distal Small Intestine
- Author
-
Bonnie Harrington and Thomas V. Nowak
- Subjects
Male ,medicine.medical_specialty ,Physostigmine ,Rodent ,Bethanechol ,In Vitro Techniques ,Bethanechol Compounds ,Active stress ,Internal medicine ,biology.animal ,Intestine, Small ,medicine ,Animals ,Methacholine Compounds ,Dose-Response Relationship, Drug ,Hepatology ,biology ,Chemistry ,Gastroenterology ,Muscle, Smooth ,Anatomy ,Acetylcholine ,Small intestine ,Rats ,Endocrinology ,medicine.anatomical_structure ,Parasympathomimetics ,Cholinergic ,Carbachol ,Methacholine ,Stress, Mechanical ,Muscle Contraction ,medicine.drug - Abstract
Proximal and distal rat small intestine was cut into strips measuring 6.0 X 10.0 mm. Strips cut along the oral-caudal axis were called longitudinal strips, whereas those cut 90 degrees to that axis were called circular strips. Stress in circular and longitudinal muscle strips was measured continuously as they were superfused with acetylcholine, carbamylcholine, methacholine, bethanechol, or physostigmine. Resting stress during stretch, acetylcholine-stimulated active stress, and total stress were determined. Proximal circular muscle was five times as sensitive to acetylcholine as distal circular muscle (p less than 0.05); proximal longitudinal muscle was 2.8 times as sensitive to bethanechol as distal muscle (p less than 0.05). Resting, active, and total stress were similar in proximal and distal muscle, but circular muscle showed nearly twice the resting stress of longitudinal muscle at either proximal or distal sites (p less than 0.05). Physostigmine (10(-6) M) increased acetylcholine-stimulated active stress in proximal and distal circular muscle by 29% and 70%, respectively (p less than 0.05), but not in longitudinal muscle (p greater than 0.05). This difference between proximal and distal circular muscle (41%) was also significant (p less than 0.05). Thus, the proximal and distal muscle of the rat small intestine differs in its sensitivity to various cholinergic agonists, but not in its length-stress properties.
- Published
- 1985
- Full Text
- View/download PDF
14. Evidence for abnormal cholinergic neuromuscular transmission in diabetic rat small intestine
- Author
-
John M. Amatruda, Thomas V. Nowak, John H. Kalbfleisch, and Bonnie Harrington
- Subjects
Male ,medicine.medical_specialty ,Contraction (grammar) ,Neuromuscular transmission ,Neuromuscular Junction ,Myenteric Plexus ,Synaptic Transmission ,Neuromuscular junction ,Diabetes Mellitus, Experimental ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Myenteric plexus ,Hepatology ,Gastroenterology ,Anatomy ,Small intestine ,Electric Stimulation ,Rats ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Cholinergic Fibers ,Tetrodotoxin ,Cholinergic ,medicine.symptom ,Digestive System ,Muscle contraction ,Muscle Contraction - Abstract
Proximal and distal rat small intestine from control, diabetic, and insulin-treated diabetic rats was cut into strips measuring 6.0 × 10.0 mm. Strips cut along the oral-caudal axis were called longitudinal strips, while those cut 90 ° to that axis were called circular strips. The strips were stretched to their optimum lengths and subjected to electrical field stimulation (0.1–1.0-ms pulse duration, 30–270 mA, 1–26 Hz) in the presence of Krebs' solution and Krebs' solution plus 10 −6 M atropine. Field stimulation produced atropine-sensitive and atropineresistant contractions in all strips. Significant differences among the three groups were found in the amplitudes of atropine-sensitive contractions in strips from distal longitudinal muscle. Controls showed the highest amplitude contractions and diabetics the lowest, whereas the insulin-treated diabetics showed contractions intermediate in amplitude. No significant differences were noted among the atropine-resistant contractions. Field stimulation delivered at pulse durations of 5.0 and 50.0 ms in the presence of neural blockade with tetrodotoxin (5 × 10 −6 M) produced similar contraction amplitudes among the three groups. These results suggest that streptozotocin-induced diabetes mellitus is associated with defective cholinergic neuromuscular transmission in the myenteric plexus of the distal small intestine. Insulin therapy seems to improve the abnormality.
- Published
- 1986
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.